SUMMARY A randomised, controlled, double-blind clinical trial designed to determine the effectiveness of phenytoin in preventing epilepsy in patients who had suffered a serious head injury is reported. One hundred and sixty-four patients were randomly assigned to treatment with phenytoin or placebo capsules for one year. Patients who had a fit within one week of injury were excluded. Drug levels were monitored throughout with appropriate dosage adjustment; however only 48% of the phenytoin group had plasma levels greater than 40,tmoUl. There were seven deaths during the study. Only 11 patients (six in the phenytoin group and five in the placebo group) developed post-traumatic epilepsy within one year; a further four patients developed seizures between 1 and 2 years after injury. This low incidence of post-traumatic epilepsy (7% (SE 2%) at one year and 10% (SE 2%) at two years) means that future clinical trials of prophylaxis will have to be much larger (at least six fold).
years. Penry and co-workers, using a similar therapeutic regimen were unable to confirm these findings.7 A prophylactic effect of phenytoin alone has been reported in two studies which used retrospective controls.89 More recently, in a controlled, prospective study Young et al'°1 l have claimed that phenytoin is ineffective in preventing early or late post-traumatic seizures.
The results reported here were derived from a randomised, controlled, double-blind clinical trial designed to compare phenytoin and placebo prophylaxis following head injury in patients considered at high risk of post-traumatic epilepsy. Treatment policies consisted of randomly allocated phenytoin or placebo prophylaxis for one year after trial entry, followed by withdrawal of treatment from all seizure-free patients and continued follow-up for a second year. A preliminary report based mainly upon the first year of follow-up of each patient was given at the XIIth Epilepsy International Symposium.12 In view of the low incidence of late onset post-traumatic epilepsy found in this study we present here results from the combined treatment series (phenytoin and placebo) following completion of two-year follow-up; we present an estimate of the risk of late onset post-traumatic epilepsy following severe head injury and discuss the resultant implications for future clinical trials of prophylaxis. 899 900 Methods Patients All patients, aged between 5 and 65 years who had suffered a head injury and were admitted to either the Department of Surgical Neurology at Edinburgh Royal Infirmary (from 1 Janurary 1977) or the Department of Neurological Surgery at Newcastle General Hospital (from 1 November 1977) were eligible for entry to the trial provided that the injury was complicated by one of the following features: dural penetration, intracranial haematoma (extradural, subdural or intracerebral), depressed skull fracture (bone depressed at least the thickness of the cranium), persistent neurological deficit (more extensive than cranial nerve injury alone) or post-traumatic amnesia (PTA) for more than 24 hours after injury. These criteria, either alone or in combination, may be associated with an increased risk of post-traumatic epilepsy.'3 Patients with a history of epilepsy (other than febrile convulsions in infancy) before injury, or who developed epilepsy in the first week after injury (early post-traumatic epilepsy) were excluded. The nature of the trial was explained to the patient, or a relative, and the patient entered in the trial only if (signed) informed consent was given.
Phenytoin or placebo treatment was administered by the hospital pharmacist using a prepared list of random treatment allocations. Capsules of 50 mg or 100 mg phenytoin and matched placebo capsules (both supplied by WarnerLambert (UK) Ltd) were prescribed on the day of admission to the trial. In children (5-15 years inclusive) the initial daily dose was 5 mgtkg body weight; for adults 300 mg as a single or divided daily dose was prescribed. The trial was conducted "double-blind" with prescribed treatment known only to the hospital pharmacy and the trial coordinators, who had no responsibility for patient care and follow-up.
Patients were seen at an out-patient clinic at 2 weeks after discharge from hospital and at 6, 12, 15, 18, and 24 months after head injury. Enquiries about seizures were made to the family doctors of the few patients who persistently failed to attend out-patient clinics. Follow-up after 24 months was achieved through routine neurological clinic attendances and family doctor enquiry. During the first year of follow-up drug dosage was adjusted to achieve "optimal" therapeutic concentration of phenytoin (40 to 80 ,umol/1); changes of capsules were also recommended for patients on placebo to preserve the double-blind design of the trial. At one year after injury phenytoin or placebo capsules were withdrawn over a two week period.
Patients were withdrawn from the trial after the development of epilepsy, which was diagnosed from the history obtained from patients, their relatives, general practioners and hospital staff. For this trial, epilepsy was diagnosed on clinical features alone; EEG changes, though looked for, were not a prerequisite. All patients with suspected epilepsy were seen by a consultant neurologist before a final diagnosis was made. The date of the fit was taken as the date of withdrawal from the trial, and patients withdrawn were followed-up for the occurrence of further seizures.
Statistics The period (in weeks) from randomisation to either the date of first seizure, death or the last date McQueen, Blackwood, Harris, Kalbag, Johnson seizure-free was calculated for each patient. Actuarial percentage seizure-free curves (life-table) were calculated for the separate treament groups and the combined series. Using information on the first two years of follow-up only, the hazard rate for late onset post-traumatic epilepsy was calculated using the maximum likelihood estimator for progressively censored data assuming an exponential distribution of times to first post-traumatic seizure;'4 this assumption was checked by assessing linearity in a plot of time to first seizure against cumulative hazard rates. An approximate 95% confidence interval for the true hazard rate was calculated using the "quick" estimate. ' the trial persisted with the drug treatment for the full year. A similar degree of non-compliance was suggested by the plasma levels of phenytoin. Only 48% of the patients in the phenytoin group achieved plasma concentrations greater than 40 ,mol/I on at least one occasion; in some patients the therapeutic level was not maintained throughout the 12 months. Thirty-six per cent had concentrations in the range 20 to 39 ,mmoVl, 12% in the range 10 to 19 ,umoVI and 4% never had concentrations above 9,umoIl.
The status of all patients 24 months after entry to the trial is shown in table 3. Only two patients did not complete their scheduled follow-up; both migrated from the Edinburgh area and could not be traced. For the remaining 162 patients two-year follow-up information was complete. Seven patients died with 7 weeks of admission to the trial. The causes of death were heart disease (4), pulmonary embolism (2) Patients who are symptom-free might be expected to comply less well in taking anticonvulsant medication than patients who have experienced seizures. However, our findings are broadly in agreement with those from studies on out-patients with epilepsy, where poor compliance has been found to be a major cause of low or fluctuating phenytoin levels and inadequate seizures control.19-2' Compliance can be improved among epileptic patients if a simplified dosage regime22 and frequent clinic visits23 are employed. Both strategies were adopted in this study with apparently only limited success. This suggests that in any large trial of epilepsy prophylaxis a low rate of compliance should be anticipated, with perhaps only half the patients taking medication as instructed for the full year.
Our results have considerable implications for clinical trials of anticonvulsant prophylaxis following serious head injury. If it is assumed that 90% of patients who do not have seizures within the first week of injury are seizure-free 2 years later without antiepileptic treatment then a clinical trial of prophylaxis must include about 1200 patients to have a 90% power of detecting (at p = 0.05) a change to at least 95 % seizure-free with anticonvulsant treatment. If it is assumed instead that the two-year seizure-free rate untreated is 85% (corresponding to the lower 95% confidence limit of our estimate) then about 1900 patients are required to detect a difference of at least 5% in seizure-free rate on antiepileptic prophylaxis (with 90% power at p = 0 05). Differences greater than 5% between 2 year seizure-free rates in untreated patients and patients given antiepileptic prophylaxis appear unlikely. These results imply that all randomised clinical trials of prophylaxis of late onset post-traumatic epilepsy conducted to date are too small (by a factor of at least six).
The benefits of routine prescription of anticonvulsant drugs in severely head injured patients remains uncertain and the implementation of such a therapeutic policy has to take into account both the high level of non-compliance and the relatively low incidence of post traumatic seizures found in these patients.
